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Abstract Hypericin (HYP) is a photosensitizing pigment from
Hypericum perforatum that displays cytotoxic effects in
neoplastic cell lines. Therefore, HYP is presently under
consideration as a new anticancer drug in photodynamic therapy.
Here, we investigated the mechanism of action of HYP photo-
induced apoptosis of Jurkat cells compared to the cytostatic drug
paclitaxel (PXL). Both photoactivated HYP and PXL similarly
increased the activity of caspase-8 and caspase-3, and drug-
induced apoptosis of Jurkat cells was completely blocked by
inhibitors of caspase-8 (Z-IETD-FMK) and caspase-3 (Z-
DEVD-FMK). The involvement of death receptors was analyzed
using neutralizing monoclonal antibodies against Fas (SM1/23),
FasL (NOK-2) and TNF-R1 (MAB225), and a polyclonal rabbit
anti-human TNF-related apoptosis-inducing ligand (TRAIL)
antiserum. TRAIL antibody blocked TRAIL-induced and HYP
photo-induced, but not PXL-induced apoptosis of Jurkat cells. In
contrast, PXL-induced, but not HYP-induced apoptosis was
blocked by the SM1/23 and NOK-2 antibodies. Anti-TNF-R1
antibody had no effect. These findings suggest that HYP photo-
induced apoptosis of Jurkat cells is mediated in part by the
TRAIL/TRAIL-receptor system and subsequent activation of
upstream caspases. ß 2001 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Hypericin (HYP) is a photosensitizing plant pigment from
Hypericum perforatum [1,2]. The absorption spectrum of HYP
shows peaks in the UV range (330 nm) and in the visible light
(VIS) range at 550 and 588 nm [2]. Upon photoactivation,
HYP generates highly reactive singlet oxygen molecules
[2,3]. The photodynamic action of HYP includes photohemol-
ysis of red blood cells [1], lipid peroxidation, increase of
superoxide dismutase activity, and decrease of cellular gluta-
thione levels [4]. Several studies have described cytotoxic ef-
fects of HYP in neoplastic cell lines [4^7]. Therefore, HYP is
presently under consideration as a new anticancer drug in
photodynamic therapy (PDT) [8,9]. During the last years,
several pharmacological actions of HYP have been described
that may contribute to its antiproliferative activity. These in-
clude inhibition of mitochondrial succinoxidase [3], protein
kinase C [10,11], tyrosine kinase [12,13], MAP kinases [14],
epidermal growth factor receptor [13], and transcription factor
NF-UB [15]. Most evidence suggests that photoactivated HYP
kills tumor cells by induction of apoptosis [7,14,16^19],
although necrosis occurs at higher drug concentrations [18].
At present, the mechanisms of HYP-induced apoptosis are
not fully understood. Although HYP is a strong inhibitor of
protein kinase C [10] it was shown that protein kinase C in-
hibition does not correlate with cytotoxicity induced by HYP
[16]. HYP-induced apoptosis of glioma cells is not dependent
on the level of bcl-2 expression [16]. However, in Jurkat cells
overexpression of bcl-2 delayed later stages of HYP photo-
induced apoptosis [19]. Recently it was shown that HYP-in-
duced apoptosis is associated with mitochondrial membrane
depolarization in glioma cells, HeLa cells and Jurkat cells [17^
19], release of cytochrome c from mitochondria of HeLa cells
[18] and activation of caspase-3 in HeLa and Jurkat cells
[14,18,19].
Here, we show that HYP photo-induced apoptosis of
Jurkat cells is associated with the activation of caspase-8
and can be blocked by a inhibitor of caspase-8, Z-IETD-
FMK. Since caspase-8 is an initiator-caspase upstream of
cell death receptors [20], we reasoned that receptors of the
tumor necrosis factor (TNF) family might be involved in
HYP-induced apoptosis.
Using neutralizing antibodies against Fas, Fas-ligand
(FasL), TNF-receptor-1 (TNF-R1) and TNF-related apopto-
sis-inducing ligand (TRAIL) we could demonstrate that HYP-
induced apoptosis can be speci¢cally inhibited by a polyclonal
anti-TRAIL antibody. We have shown that this antibody spe-
ci¢cally blocks TRAIL-mediated killing of Jurkat cells. For
comparison, paclitaxel (PXL)-induced apoptosis was studied.
PXL and other drugs that disturb microtubule dynamics kill
cells in a Fas/FasL-dependent manner [21].
2. Materials and methods
2.1. Chemicals and antibodies
HYP was obtained from Roth (Karlsruhe, Germany). PXL was
obtained from Tocris (Tocris Cookson, MO, USA). Stock solutions
were prepared in DMSO and stored in the dark at 320‡C. Further
dilutions were made with medium to obtain ¢nal concentrations as
indicated. Cell-permeable non-toxic inhibitors of caspase-8 (Z-IETD-
FMK) and caspase-3 (Z-DEVD-FMK) were obtained from RpD
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systems (Wiesbaden, Germany) and were used at a concentration of
50 WM. For blocking experiments, the neutralizing monoclonal anti-
bodies (mAb) NOK-2 (anti-FasL) (Pharmingen, San Diego, CA,
USA), SM1/23 (anti-Fas) (Alexis, Gru«nberg, Germany) and
MAB225 (anti-TNF-R1) (RpD systems) were used at a concentration
of 10 Wg/ml. The polyclonal anti-human TRAIL antiserum 210-732-
R100 (Alexis) was used at a 1:50 dilution. Recombinant human solu-
ble TRAIL (rhsTRAIL) (Alexis) was used at a concentration of 100
ng/ml, in the presence of 2 Wg/ml enhancer antibody (Alexis).
2.2. Cell culture and drug treatment
Jurkat cells (human acute T cell leukemia) (ATCC, Manassas, VA,
USA) were cultured in c-RPMI (RPMI supplemented with 10% FCS,
1% L-glutamine and 1% penicillin/streptomycin) (Gibco, Eggenstein,
Germany) at 37‡C and 5% CO2. Before treatment with HYP and VIS,
the cells were washed and resuspended in PBS. HYP was prepared
and added to cell cultures (250^1000 ng/ml ¢nal) under strictly sub-
dued conditions. After 2 h incubation in the dark the cells were irra-
diated on ice with VIS (520^750 nm, 5.0 J/cm2), delivered from the
incoherent light source PDT 1200 SOA (Waldmann, VS-Schwennin-
gen, Germany) [22]. Following irradiation, the cells were washed and
further cultured in c-RPMI in 96 well £at-bottom microtiter plates
(Greiner, Nu«rtingen, Germany). For PXL treatment, the cells were
washed and suspended in c-RPMI before PXL was added (1 WM
¢nal). The cell numbers were 1U106/ml (DNA preparation, caspase
assay), 1U105/ml (proliferative assay) or 1U104/ml (apoptosis assay).
2.3. Proliferative assay
Following drug treatment, the cells were incubated for 24 h in the
dark. Cells were then pulsed with 1 WCi [3H]TdR/well for 18 h and
[3H]TdR incorporation was determined by liquid scintillation spec-
troscopy using a Top-Count (Canberra Packard, Frankfurt, Ger-
many) as described [22]. Data are expressed as mean þ S.D. of three
independent experiments.
2.4. Photometric determination of apoptosis
Cells were treated with drugs or additives for 24 h as described
above. Cells were then evaluated for apoptosis using a cell death
detection ELISA (Cell Death Detection ELISAplus, Boehringer,
Mannheim, Germany). The principle of this test is the detection of
mono- and oligonucleosomes in the cytoplasmic fractions of cell ly-
sates using biotinylated anti-histone and peroxidase-coupled anti-
DNA antibodies. The amount of nucleosomes is photometrically
quanti¢ed at 405 nm by the peroxidase activity retained in the immu-
nocomplexes. Data are expressed as mean þ S.D. of three independent
experiments.
2.5. DNA gel electrophoresis
Apoptotic DNA fragments were isolated from 106 cells treated with
HYP (500 ng/ml)+VIS (5 J/cm2) as described [23]. Brie£y, cells were
washed and pelleted by centrifugation. Cell pellets were treated for 10
s with lysis bu¡er (1% NP40; 20 mM EDTA; 50 mM Tris^HCl, all
from Sigma, St. Louis, MO, USA). The cells were then mixed with 1%
SDS (Sigma), treated for 2 h with RNase (5 Wg/Wl) (Boehringer,
Mannheim, Germany) at 56‡C and digested with proteinase K (2.5
Wg/Wl) (Sigma) for 2 h at 37‡C. After addition of 10 M ammonium
acetate (Merck, Darmstadt, Germany) the DNA was precipitated with
100% ethanol at 320‡C, resuspended in gel loading bu¡er (10 mM
Tris^HCl, 1 mM EDTA, Sigma) and separated with KiloBase1 DNA
marker (Pharmacia, Freiburg, Germany) on a 1% agarose gel.
2.6. Terminal dUTP nick end labeling (TUNEL) assay
To assess apoptosis of HYP (500 ng/ml)+VIS (5 J/cm2)-treated
Jurkat cells at the single cell level, DNA strand breaks were identi¢ed
using the TUNEL technique. The in situ cell death detection kit from
Boehringer Mannheim (Mannheim, Germany) was used according to
the manufacturer’s instructions. Permeabilized, propidium iodide-pos-
itive cells were analyzed for dUTP-FITC staining using the Cell
Quest1 research software on a FACScan1 £ow-cytometer (both Bec-
ton Dickinson).
2.7. Caspase assay
To determine the enzymatic activity of caspase-3 and caspase-8,
colorimetric assays were performed. Jurkat cells (1U105/ml) were
treated for 24 h with HYP (500 ng/ml)+VIS (5.0 J/cm2) or 1 WM
PXL. Cells were lysed in ice-cold hypotonic bu¡er containing 20
mM Tris^HCl (pH 7.2), 1 mM EDTA and 10 Wg protease inhibitors
(Boehringer) to prevent non-speci¢c cleavage of proteins. Homoge-
nates were clari¢ed by centrifugation for 10 min at 16 000Ug. Cell
lysates were then tested for protease activity by the addition of cas-
pase-speci¢c peptides conjugated to the color reporter p-nitroanilide
(RpD systems). The cleavage of the peptide by the caspase releases
the chromophore, which is quantitated spectrophotometrically at 405
nm. The level of caspase enzymatic activity is directly proportional to
the color reaction. Data are indicated as percent of untreated control
and represent mean+S.D. of three independent experiments.
2.8. Blocking of TRAIL-mediated cell killing
To con¢rm the blocking activity of the anti-TRAIL antibody,
Jurkat cells were incubated for 24 h with 100 ng/ml TRAIL+enhancer
antibody in the presence or absence of the anti-TRAIL antibody
(1:500, 1:100 and 1:50). Subsequently, cell proliferation was mea-
sured by [3H]TdR uptake as described above.
3. Results
3.1. Photoactivated HYP inhibits proliferation of Jurkat cells
by induction of apoptosis
Treatment of Jurkat cells with HYP (250^1000 ng/ml) and
subsequent irradiation with VIS (520^750 nm, 5.0 J/cm2)
showed a dose-dependent inhibition of cell proliferation,
whereas HYP alone had not e¡ect (Fig. 1A). We next eval-
uated cell lysates of HYP+VIS-treated Jurkat cells for the
content of apoptotic oligonucleosomes by a colorimetric ELI-
SA. Fig. 1B shows a dose-dependent increase of DNA-frag-
mentation after treatment with HYP+VIS. Apoptosis was fur-
ther con¢rmed by DNA-gel electrophoresis, showing an
increased generation of apoptotic DNA fragments in HYP+
VIS-treated cells, but not in cells treated with HYP alone
(Fig. 1C). TUNEL-staining revealed that treatment with HYP
(500 ng/ml)+VIS (5 J/cm2) resulted in an apoptosis rate of
80% as compared with 10% in untreated cells (Fig. 1D).
3.2. Photoactivated HYP induces activation of caspase-8 and
caspase-3
To assess the involvement of caspases, Jurkat cells were
treated with HYP (500 ng/ml)+VIS (5 J/cm2) and 1 WM
PXL. The cells were then incubated for 24 h and cell lysates
were evaluated for the enzymatic activity of caspase-8 and
caspase-3, respectively. Caspase-8 and caspase-3 activity
were increased by treatment with HYP+VIS to a similar ex-
tent as compared with PXL (Fig. 2).
3.3. HYP photo-induced apoptosis is blocked by
caspase-inhibitors and anti-TRAIL antibody
Both HYP+VIS and PXL-induced apoptosis could be
blocked by inhibitors of caspase-8 (Z-IETD-FMK) and cas-
pase-3 (Z-DEVD-FMK) (Fig. 3). Since caspase-8 is an initia-
tor-caspase upstream of death receptors of the TNF family
[20], we asked if HYP-induced apoptosis is mediated by death
receptors containing a cytoplasmic death domain.
As shown in Fig. 3, polyclonal anti-TRAIL Ab selectively
inhibited HYP-induced apoptosis. In contrast, anti-FasL mAb
(NOK-2) and anti-Fas mAb (SM1/23) blocked PXL-induced
apoptosis, but had no e¡ect on HYP+VIS-induced apoptosis.
Anti-TNF-R1 mAb had no e¡ect on HYP+VIS and PXL-
induced apoptosis (Fig. 3). The inhibitory activity of the poly-
clonal anti-TRAIL Ab was con¢rmed in a separate experi-
ment that shows a dose-dependent inhibition of TRAIL-medi-
ated killing of Jurkat cells by the antibody (Fig. 4).
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4. Discussion
Here we show that photoactivated HYP dose-dependently
inhibits proliferation of Jurkat cells by induction of apoptosis.
Triggering of apoptosis by anticancer drugs may enter the cell
death pathway at di¡erent sites. The ‘extrinsic’ cell death
pathway involves the TNF-family of death receptors [20,24^
26] and subsequent activation of the initiator caspase-8
[26,27]. Alternatively, the apoptosis program can be activated
by the ‘intrinsic’ cell death pathway directly targeting mito-
chondria. This pathway results in the release of pro-apoptotic
factors from mitochondria, i.e. cytochrome c and apoptosis-
inducing factor (AIF), and caspase activation downstream of
mitochondria, i.e. caspase-9, that is part of the mitochondria-
associated apoptosome complex [27^32]. Vantieghem et al.
demonstrated that HYP-induced apoptosis of HeLa cells
can be inhibited by a speci¢c inhibitor of caspase-3 (Z-
DEVD-FMK) and by the pan-caspase inhibitor (Z-VAD-
FMK), whereas HeLa cells over-expressing the serpin-like in-
hibitor CrmA, which preferentially inhibits caspase-1 and cas-
Fig. 1. E¡ect of photoactivated HYP on cell proliferation and apoptosis of Jurkat cells. A: Proliferative assay. Cell proliferation was assessed
24 h after treatment with HYP+VIS by [3H]TdR incorporation. Data are expressed as mean þ S.D. of three independent experiments. B: Dose-
dependent increase of apoptotic oligonucleosomes 24 h after treatment with HYP+VIS. Cell lysates were evaluated for the content of oligonu-
cleosomes by a cell death detection ELISA. Data represent mean þ S.D. of three independent experiments. C: Evaluation of HYP-induced apo-
ptosis by DNA-electrophoresis. DNA was extracted from Jurkat cells 24 h after treatment with HYP (500 ng/ml)+VIS (5 J/cm2) by NP40 lysis.
DNA was separated on a 1% agarose gel. M, KiloBase1 DNA marker; lane 1, cells treated with HYP alone; lane 2, cells treated with HY-
P+VIS. D: Evaluation of HYP-induced apoptosis at the single cell level. Untreated cells (left) and cells treated with HYP (500 ng/ml)+VIS (5
J/cm2) (right) were incubated for 24 h. Subsequently, the cells were permeabilized, stained with propidium iodide and FITC-dUTP and ana-
lyzed on a FACScan. The percentage of TUNEL-positive cells is indicated.
Fig. 2. Involvement of caspases in HYP photo-induced apoptosis of
Jurkat cells. Cells were treated with HYP (500 ng/ml)+VIS (5
J/cm2) or PXL (1 WM) for 24 h. Cell lysates were tested for protease
activity by the addition of caspase-speci¢c peptides. The cleavage of
the peptide by the caspase releases a chromophore, which is quanti-
tated at 405 nm. Data are indicated as percent of untreated control
and represent mean+S.D. of three independent experiments.
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pase-8, did not protect the cells from apoptosis [18]. The au-
thors conclude that HYP-induced apoptosis is not mediated
by the ‘extrinsic’ caspase-8-dependent pathway but rather by
the ‘intrinsic’ cell death pathway that involves the release of
cytochrome c from the mitochondria and subsequent activa-
tion of caspase-3 [18]. However, Chaloupka et al. have shown
that HYP-induced mitochondrial damage of Jurkat cells does
not act through the mitochondrial permeability transition
(MPT) pore, but rather through non-speci¢c photo-induced
alterations of mitochondrial membranes and a rapid change
of the intracellular pH [19]. This is consistent with the earlier
¢nding that the disruption of mitochondrial function is linked
to the photooxidative properties of HYP [3]. These ¢ndings
suggest that the e¡ect of photoactivated HYP on mitochon-
dria may be non-speci¢c or indirect in some cell types (i.e.
Jurkat cells), while it can be mediated by the classical ‘intrin-
sic’ cell death pathway in other cells (i.e. HeLa cells).
Our ¢nding that HYP-induced apoptosis of Jurkat cells is
associated with the activation of caspase-8 prompted us to
investigate the involvement of receptors of the TNF family
in HYP-induced apoptosis. Using neutralizing antibodies
against Fas, FasL, TNF-R1 and TRAIL we have shown
that HYP-induced apoptosis can be speci¢cally inhibited by
a polyclonal anti-TRAIL antibody. The speci¢city of the in-
hibitory activity of this antibody was demonstrated by block-
ing TRAIL-mediated killing of Jurkat cells. The mechanism
by which photoactivated HYP acts on the TRAIL/TRAIL-
receptors of Jurkat cells is not clear at the present. It may
include increased shedding of TRAIL, stabilization of death-
inducing TRAIL-receptors or downregulation of decoy recep-
tors. The signal transduction pathways for the two pro-apo-
ptotic TRAIL receptors (TRAIL-R1/DR4 and TRAIL-R2/
DR5) seem to use FADD (Fas-associated death domain), an
adapter protein that bridges the receptor with procaspase-8
[33,34]. TRAIL-induced apoptosis involves activation of cas-
pase-8 and caspase-3, is followed by mitochondrial membrane
potential dissipation and cytochrome c release, and cannot be
blocked by bcl-2 overexpression [33]. Thus, the release of cy-
tochrome c from mitochondria that occurs during HYP pho-
to-induced apoptosis may also be explained by the apoptosis
pathway that involves the TRAIL/TRAIL-receptor system.
Tumor cells overexpressing bcl-2 are often resistant to apo-
ptosis induced by chemotherapeutic drugs, but TRAIL may
still kill chemoresistant tumors since it bypasses the ‘intrinsic’
cell death pathway that is controlled by bcl-2 [35]. TRAIL-
mediated killing of tumor cells is associated with low toxicity
in vivo [36^38]. The present study reports for the ¢rst time
TRAIL-mediated cell death triggered by HYP in a single cell
line. At the present it is not clear if this is also the case in
other cell lines. It would also be interesting to study the e¡ects
of HYP on cells that are resistant to TRAIL. Taken together,
the present study adds to the multi-facetted action of HYP by
demonstrating that HYP photo-induced apoptosis of Jurkat
cells is mediated at least in part by the TRAIL/TRAIL-recep-
tor system and activation of caspase-8.
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